These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

531 related articles for article (PubMed ID: 31499095)

  • 1. ATP-citrate lyase (ACLY) in lipid metabolism and atherosclerosis: An updated review.
    Feng X; Zhang L; Xu S; Shen AZ
    Prog Lipid Res; 2020 Jan; 77():101006. PubMed ID: 31499095
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Bempedoic acid: effects on lipoprotein metabolism and atherosclerosis.
    Burke AC; Telford DE; Huff MW
    Curr Opin Lipidol; 2019 Feb; 30(1):1-9. PubMed ID: 30586346
    [TBL] [Abstract][Full Text] [Related]  

  • 3. ATP-citrate lyase: genetics, molecular biology and therapeutic target for dyslipidemia.
    Burke AC; Huff MW
    Curr Opin Lipidol; 2017 Apr; 28(2):193-200. PubMed ID: 28059952
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Adenosine Triphosphate Citrate Lyase and Fatty Acid Synthesis Inhibition: A Narrative Review.
    Duarte Lau F; Giugliano RP
    JAMA Cardiol; 2023 Sep; 8(9):879-887. PubMed ID: 37585218
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The multifaceted therapeutic value of targeting ATP-citrate lyase in atherosclerosis.
    Verberk SGS; Kuiper KL; Lauterbach MA; Latz E; Van den Bossche J
    Trends Mol Med; 2021 Dec; 27(12):1095-1105. PubMed ID: 34635427
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prevention of Diet-Induced Metabolic Dysregulation, Inflammation, and Atherosclerosis in
    Samsoondar JP; Burke AC; Sutherland BG; Telford DE; Sawyez CG; Edwards JY; Pinkosky SL; Newton RS; Huff MW
    Arterioscler Thromb Vasc Biol; 2017 Apr; 37(4):647-656. PubMed ID: 28153881
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Bempedoic Acid Lowers Low-Density Lipoprotein Cholesterol and Attenuates Atherosclerosis in Low-Density Lipoprotein Receptor-Deficient (
    Burke AC; Telford DE; Sutherland BG; Edwards JY; Sawyez CG; Barrett PHR; Newton RS; Pickering JG; Huff MW
    Arterioscler Thromb Vasc Biol; 2018 May; 38(5):1178-1190. PubMed ID: 29449335
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Liver-specific ATP-citrate lyase inhibition by bempedoic acid decreases LDL-C and attenuates atherosclerosis.
    Pinkosky SL; Newton RS; Day EA; Ford RJ; Lhotak S; Austin RC; Birch CM; Smith BK; Filippov S; Groot PHE; Steinberg GR; Lalwani ND
    Nat Commun; 2016 Nov; 7():13457. PubMed ID: 27892461
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Safety and Efficacy of Bempedoic Acid to Reduce LDL Cholesterol.
    Ray KK; Bays HE; Catapano AL; Lalwani ND; Bloedon LT; Sterling LR; Robinson PL; Ballantyne CM;
    N Engl J Med; 2019 Mar; 380(11):1022-1032. PubMed ID: 30865796
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Bempedoic Acid in the Treatment of Patients with Dyslipidemias and Statin Intolerance.
    Susekov AV; Korol LA; Watts GF
    Cardiovasc Drugs Ther; 2021 Aug; 35(4):841-852. PubMed ID: 33502687
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Bempedoic acid: effect of ATP-citrate lyase inhibition on low-density lipoprotein cholesterol and other lipids.
    Paton DM
    Drugs Today (Barc); 2020 Sep; 56(9):573-582. PubMed ID: 33025951
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Bempedoic acid, an ATP citrate lyase inhibitor, reduces intimal hyperplasia via activation of AMPKα signaling pathway.
    Liu W; Liu M; Xiong H; Xia L; Yang Q; Chen M; Cai Y; Li S
    Int Immunopharmacol; 2022 Dec; 113(Pt A):109392. PubMed ID: 36461594
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Bempedoic Acid: A New Non-statin Drug for the Treatment of Dyslipidemia.
    Wichaiyo S; Supharattanasitthi W
    Clin Drug Investig; 2021 Oct; 41(10):843-851. PubMed ID: 34435333
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Bempedoic acid: Review of a novel therapy in lipid management.
    Delevry D; Gupta EK
    Am J Health Syst Pharm; 2021 Jan; 78(2):95-104. PubMed ID: 33399194
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Role of Bempedoic Acid in Dyslipidemia Management.
    Kelly MS; Sulaica EM; Beavers CJ
    J Cardiovasc Pharmacol; 2020 Oct; 76(4):376-388. PubMed ID: 32732494
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Bempedoic acid and its role in contemporary management of hyperlipidemia in atherosclerosis.
    Tummala R; Gupta M; Devanabanda AR; Bandyopadhyay D; Aronow WS; Ray KK; Mamas M; Ghosh RK
    Ann Med; 2022 Dec; 54(1):1287-1296. PubMed ID: 35533049
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Bempedoic Acid Unveils Therapeutic Potential in Non-Alcoholic Fatty Liver Disease: Suppression of the Hepatic PXR-SLC13A5/ACLY Signaling Axis.
    Sun Q; Guo Y; Hu W; Zhang M; Wang S; Lei Y; Meng H; Li N; Xu P; Li Z; Lin H; Huang F; Qiu Z
    Drug Metab Dispos; 2023 Dec; 51(12):1628-1641. PubMed ID: 37684055
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Bempedoic acid for the treatment of dyslipidemia.
    Marrs JC; Anderson SL
    Drugs Context; 2020; 9():. PubMed ID: 32922503
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Bempedoic Acid: a cholesterol lowering agent with a novel mechanism of action.
    Nguyen H; Akamnonu I; Yang T
    Expert Rev Clin Pharmacol; 2021 May; 14(5):545-551. PubMed ID: 33691561
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Association of Bempedoic Acid Administration With Atherogenic Lipid Levels in Phase 3 Randomized Clinical Trials of Patients With Hypercholesterolemia.
    Banach M; Duell PB; Gotto AM; Laufs U; Leiter LA; Mancini GBJ; Ray KK; Flaim J; Ye Z; Catapano AL
    JAMA Cardiol; 2020 Oct; 5(10):1124-1135. PubMed ID: 32609313
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 27.